STATEMENT OF NEED
There are an estimated 13,240 new cases of cervical cancer in the United States each year, and 4,170 people die of the disease. Due to screening and heightened awareness, deaths have declined during the past few decades. However, the malignancy continues to be a global health concern and is considered an epidemic in parts of the world. A significant proportion of patients develop advanced disease, which is rarely curable with available therapies, and treatment is often limited to palliative care. The 5-year overall survival rate is 57% for women with regional disease and 17% for those with distant disease; amongst black women, the prognosis is worse.
Medical oncologists, gynecologic oncologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with cervical cancer.
Upon completion of this activity, participants should be able to:
Ramez Eskander, MD (Chairperson)
Assistant Professor of Obstetrics, Gynecology, and Reproductive Sciences
University of California San Diego
Bradley Monk, MD, FACS, FACOG
Professor, Gynecologic Oncology
University of Arizona and Creighton University
There is no fee to participate in or claim CME/CE credit for this activity.
Jointly Provided by
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and i3 Health. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.4 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1 ILNA point toward:
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Ramez Eskander, MD has no relevant financial relationships to disclose.
Bradley Monk, MD, FACS, FACOG discloses that he has served as a speaker/consultant for AbbVie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis, Genmab, Gradalis, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson & Johnson, Mateon, Merck, Myriad, Perthera, Pfizer, Precision Oncology, Puma, Roche/Genentech, Samumed, Takeda, TESARO, Inc, and VBL.
Planners and Managers
The PIM planners and managers have nothing to disclose. The i3 Health planners and managers have nothing to disclose.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
UNAPPROVED USE DISCLOSURE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Merck.